• Angel of Ephesus

Society: Keeping People Diseased so the Money Keeps Rolling In: 1 Timothy 6:10

1 Timothy 6:10  For the love of money is the root of all evil: which while some coveted after, they have erred from the faith, and pierced themselves through with many sorrows.


While many people suffer from disease the pharma companies keep lining their pockets with money. Have you heard of anything being cured lately? I havent and neither will you because once someone does cure a disease, they are shut up and the research is taken.


Have you heard that one research team in Mexico has claimed to find a cure for HPV? I didn't either until I was watching Truthstream Media on YouTube. I Googled it and found nothing from the USA about this breakthrough.


New Delhi: In a significant breakthrough, a researcher from the National Polytechnic Institute (IPN) reportedly claimed to have found a complete cure for human papillomavirus (HPV), which may help prevent the spread of cervical cancer among women. Eva Ramon Gallegos, a Mexican scientist was able to completely eliminate the virus in 29 patients infected with HPV.

Reportedly, Gallegos has been studying the effects of photodynamic therapy for two decades to help tackle different types of tumours such as breast and melanoma cancer. Gallegos, who specialises in the study of photodynamic therapy, treated 420 patients in Oaxaca and Veracruz, as well as 29 women in Mexico, using the technique.

The results were promising as the researchers found that the photodynamic therapy was able to eradicate the virus in 100% of the those who were HPV carriers without any premalignant lesions of cervical cancer, 64.3% in women with both HPV and lesions, and 57.2% in patients who had lesions without the HPV infection.

https://www.timesnownews.com/health/article/mexican-scientist-finds-100-per-cent-cure-for-human-papillomavirus-hpv-infection-cervical-cancer/363876


The Reason you will not hear about cures is because when people are sick, profits are made.


Pharmaceutical companies are developing new drugs in only two therapeutic areas these days -- cancer and rare diseases. Why? These are the only therapeutic areas where exorbitant pricing is tolerated by payers.

How exorbitant are we talking about? Most new drugs for cancer and rare diseases are being priced above $400,000 a year per patient. Some drugs are being priced at $1 million per treatment. And prices continue to soar.

https://www.medpagetoday.com/blogs/revolutionandrevelation/72407


Goldman Asks: Is Curing Diseases Worth it?


Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'


Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.

"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html


Keytruda and Gardasil Likely Continue to Drive Merks Earning Growth

Merck (NYSE:MRK) continues to see steady top line growth, primarily led by Keytruda and Gardasil sales. The company’s Q3 results were more or less in line with our estimates, led by a strong growth in these two drugs. Looking forward, we continue to believe Keytruda will be the key growth driver for Merck in the near term. The company, in its recent earnings conference call, narrowed its full year 2018 revenue guidance to be in the range of $42.1 to $42.7 billion, and EPS guidance to be in the range of $4.30 and $4.36, and we forecast the figures to be closer to the lower end of the range. We have created an interactive dashboard ~ What Will Drive Merck’s Near Term Growth ~ on the company’s expected performance in 2018 and 2019. You can adjust the revenue and margin drivers to see the impact on the company’s earnings, and price estimate.

https://www.forbes.com/sites/greatspeculations/2018/10/30/keytruda-and-gardasil-will-likely-continue-to-drive-mercks-earnings-growth/#660fc9407fbf


KEYTRUDA BLOCKS THE PD-1 PATHWAY TO HELP PREVENT CANCER CELLS FROM HIDING. KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway and to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.

https://www.keytruda.com/how-does-keytruda-work/


With the HPV vaccine, you have the chance to help protect your child from future HPV-related cancers and diseases. GARDASIL 9 is the only vaccine that helps protect against the 9 types of HPV that are responsible for the majority of HPV-related cancers and diseases.

https://www.gardasil9.com/about-gardasil9/


Deuteronomy 15:11 For the poor shall never cease out of the land: therefore I command thee, saying, Thou shalt open thine hand wide unto thy brother, to thy poor, and to thy needy, in thy land.


Matthew 10:8 Heal the sick, cleanse the lepers, raise the dead, cast out devils: freely ye have received, freely give.


These companies do not honor Yah. They worship money and would rather see innocent lives destroyed than helping them get better. When it is all about the money, Yah is Not There.




Truthstream Media- They Actually Admitted There is No Money In Curing People

https://www.youtube.com/watch?v=wY-owubmfNg


#God

#Cancer

#Merk

#HPV



0 views

© 2023 by Name of Site. Proudly created with Wix.com

livinginoppressednationstares@gmail.com